Navigation Links
Thoratec Reports 44 Percent Increase in Second Quarter Revenues;
Date:7/31/2008

cular Division year- over-year," said Gary F. Burbach, president and chief executive officer.

"The key contributor to this growth was our successful launch of the HeartMate II LVAS (Left Ventricular Assist System) for bridge-to- transplantation (BTT) following its approval by the FDA in April. Our program to bring on new centers is ahead of expectations, as we added 26 during the quarter. We have also seen increased activity at existing centers and benefited from favorable pricing for the HeartMate II. In addition, we are seeing continued strong adoption of the HeartMate II in Europe," he added.

Burbach said that the company believes that factors contributing to increased utilization of mechanical circulatory support include the ongoing flow of favorable data around the HeartMate II, increasing clinician comfort with the device-based on the patient experience and ease of the procedure-and an improved reimbursement environment.

"Our financial performance also reflects solid growth at our International Technidyne Corporation (ITC) Division. Our ProTime(R) alternate site business had strong growth, as did our HEMOCHRON(R) coagulation product line, and our AVOX co-oximetry systems," Burbach noted.

The company also updated enrollment in the Destination Therapy (DT) arm of its Pivotal clinical trial for the HeartMate II. As of July 25, 2008, there were 570 patients enrolled in the DT arm of the trial. Enrollment in the randomized portion of the DT arm was 350 patients.

FINANCIAL HIGHLIGHTS

Thoratec reported revenues of $82.6 million in the second quarter of 2008 compared with revenues of $57.3 million in the second quarter of 2007. Cardiovascular Division revenues were $57.5 million versus $34.2 million in the same period a year ago. Revenues at ITC were $25.1 million versus $23.1 million a year ago.

GAAP gross margin for the second quarter of 2008 was 61.5 percent versus 58.8 percent a year ago. Non-GAAP gross margin, whic
'/>"/>

SOURCE Thoratec Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Thoratec Schedules Second Quarter 2008 Conference Call, Webcast
2. Thoratec Schedules First Quarter 2008 Conference Call, Webcast
3. Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation
4. URGENT Thoratec Corporation Worldwide Recall of Implantable Ventricular Assist Device
5. Thoratecs ITC Division Receives FDA Warning Letter
6. Thoratec Schedules Third Quarter Conference Call, Webcast
7. HCA Reports Second Quarter 2008 Results
8. Encision Reports First Fiscal Quarter Results
9. Osteotech Reports 2008 Second Quarter Diluted Earnings Per Share of $.10 on Revenues of $27.6 Million
10. Orchid Cellmark Reports Second Quarter 2008 Financial Results
11. Nutraceutical Reports Q3 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , ... July 06, 2015 , ... ... that eliminates 100% of all acids, chemicals and impurities; it also properly mineralizes ... water because it contains harmful contaminants.  These harmful contaminants are a byproduct of ...
(Date:7/6/2015)... ... July 06, 2015 , ... Shortly after opening her second practice in ... of doctors working on a lien basis. Dr. Lim had previously worked with ... of two Cambodian refugees, Dr. Lim suffered with back pain herself throughout high school. ...
(Date:7/6/2015)... ... July 06, 2015 , ... Olive Fertility Centre is proud to announce that ... Award on behalf of the department of Family Practice. , “This award is a ... practicing in. The technology is changing so rapidly and we are also developing new ...
(Date:7/6/2015)... CA (PRWEB) , ... July 06, 2015 , ... Seedstock ... deliver the keynote address at the 4th Annual Seedstock Sustainable Agriculture Conference – “Innovation ... year’s conference , held at the University of California-San Diego, will explore solutions ...
(Date:7/6/2015)... , ... July 06, 2015 , ... With a new ... up with Livonia Save Our Youth and announced a new charity campaign to raise ... regards to alcohol and drug abuse. Livonia Save Our Youth is a coalition created ...
Breaking Medicine News(10 mins):Health News:Pristine Water Filters.com Offers The 1st Water Revival System That Re-Mineralizes Drinking Water and Eliminates All Impurities and Chemicals 2Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 3Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 4Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 2Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 3
... (HealthDay News) -- American consumers don,t pay as much ... a new study finds. Researchers asked 203 people ... displayed on a computer screen. The information included the ... ingredients, and a description of the product that included ...
... in the United States who have the cornea-damaging disease keratoconus ... that is already proving effective in Europe and other parts ... in almost 70 percent of patients treated for keratoconus in ... is in clinical trials in the United States and is ...
... New research from the Heart and Stroke Foundation and ... people with spinal cord injury (SCI) have a higher risk ... nervous system is a key predictor of cardiovascular risk, researcher ... the Heart and Stroke Foundation and the Canadian Cardiovascular Society. ...
... , SATURDAY, Oct. 22 (HealthDay News) -- While there are ... an expert says. "They can enjoy Halloween and enjoy ... Dr. Kenneth McCormick, a pediatric endocrinologist and senior scientist at ... in a university news release. "We give parents and ...
... young adulthood and diet appeared to be associated with ... at the 10th AACR International Conference on Frontiers in ... causes of non-Hodgkin lymphoma (NHL) are poorly understood, and ... to prevent or lower the risk for this disease," ...
... Women hospital staff working night shifts may be compromising ... health of patients, Dr. Joan Tranmer told the Canadian ... Foundation and the Canadian Cardiovascular Society. Dr. Tranmer,s ... factors for heart disease in female hospital employees who ...
Cached Medicine News:Health News:Do You Really Read Nutrition Labels? 2Health News:Vitamin B-based treatment for corneal disease may offer some patients a permanent solution 2Health News:Spinal cord injuries associated with increased risk of heart disease 2Health News:Spinal cord injuries associated with increased risk of heart disease 3Health News:Healthy Halloween Advice for Children With Diabetes 2Health News:Body weight, diet may be risk factors for non-Hodgkin lymphoma 2Health News:Female shift workers may be at higher risk of heart disease 2Health News:Female shift workers may be at higher risk of heart disease 3
(Date:7/6/2015)... July 6, 2015 Array BioPharma,s (NASDAQ: ... this past weekend at the 2015 ESMO World ... At the meeting, data were shared from a ... 100-patient randomized Phase 2 expansion of that trial ... EGFR inhibitor, with or without the addition of ...
(Date:7/6/2015)... 6, 2015 Akcea Therapeutics, a wholly-owned ... ), announced today that the U.S. Food and ... volanesorsen (ISIS-APOCIII Rx ) for the treatment of ... a rare genetic disease characterized by extremely high ... Phase 2 study published in the NEJM in ...
(Date:7/4/2015)... BARCELONA , España, July 4, 2015 /PRNewswire/ ... SIR-Spheres® Y-90 a la quimioterapia de primera línea ... en el hígado (mCRC) extiende la supervivencia libre ... pacientes con cáncer colorrectal metastásico no resecable (mCRC) ... la mayor mejora en la supervivencia libre de ...
Breaking Medicine Technology:Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 2El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 3El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 4El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 5
... February 27 Novagali Pharma, a French,pharmaceutical ... first set of,data pertaining to Nova21027, its ... Novagali communicated about "Ocular ... conventional formulations of prostaglandin,analogues: an in vivo ...
... /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: ... of its new drug application ("NDA") for AFRESA(R), an ultra ... As previously announced, our internal goal was to submit the ... end of February. Based on editorial decisions made during ...
Cached Medicine Technology:Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma 2MannKind Updates Status of NDA Submission for AFRESA 2MannKind Updates Status of NDA Submission for AFRESA 3
... determination of Ang II is ... the pharmacological effect and efficiency ... angiotensin converting enzyme inhibitors (ACE ... antagonists as well as for ...
... antigen test is a visual ... presumptive qualitative detection of Respitory ... specimens in neonatal and pediatric ... test has a built-in procedural ...
Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
... BD Directigen EZ RSV Test utilizes a new, ... one device for rapid RSV detection. The testing ... method whereby dried reagents have already been applied ... a two-step process, with clear-cut results shown by ...
Medicine Products: